pharma · Hypertension · Gastric Ulcer
Yung Shin Pharmaceutical
Yung NA
Yung NA is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertension, Gastric Ulcer, Atrial Fibrillation, Essential Hypertension, Dyslipidemia, Essential Hypertension. NovaPharmaNews
Taichung, CN HQ
1952 Founded
264 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Taichung, CN
- Founded
- 1952
- Employees
- 264
- Programs
- 10
- Drugs
- 13
- Patents
- 0
Fimasartan and Rosuvastatin
Phase 3 · small molecule · Essential Hypertension, Dyslipidemia
Fimasartan and Rosuvastatin for Essential Hypertension, Dyslipidemia is a Phase 3 program (small_molecule) at Yung NA with 1 ClinicalTrials.gov record(s).
Internal code BR-FRC-CT-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Yung NA
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Essential Hypertension, Dyslipidemia
- Status
- completed
- Trials
- 1